The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes

Hadassah Medical Center

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Myelodysplastic Syndrome

Treatments: Drug: curcumin; coenzyme q10

Study type: Interventional

Funder types: Other

Identifiers

NCT00247026

385-mds 1-HMO-CTIL

mds 1

Details and patient eligibility

About

To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes. we propose to explore the efficacy of the natural compounds curcumin and CoQ10 in MDS because these two agents possess many of the effects that are desirable in MDS.

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• MDS patients with RA, RARS or RAEB will be eligible for treatment with CoQ10 as long as their IPSS score ≤ 1.5.

Exclusion criteria

• Pregnant women and nursing women will be excluded.
• History of clinically significant liver or kidney disease.
• ECOG>2
• IPSS score >1.5
• Poorly controlled diabetes mellitus, hypertension, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to the protocol.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)